Orexo

Uppsala, Sweden – May 9, 2025 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that Friedrich von Bohlen, CEO of Molecular Health AG and active in three boards, including Orexo’s since the end of 2024, has been appointed chairman of the board. The resolution was adopted at the annual general meeting held on May 8, 2025. Friedrich von Bohlen replaces James Noble, who has held the position since 2020 and has declined re-election.

Friedrich von Bohlen, based in Germany, has over 25 years of experience from successful biotech companies, both nationally and internationally. He has played a central role in the growth of several companies, as co-founder, CEO, and chairman, and has participated in several IPOs in Europe and the US. He also has extensive experience in global investments in biotechnology. Friedrich holds a PhD in neurobiology from ETH Zurich and a diploma in biochemistry from the University of Zurich.

Friedrich von Bohlen, the new chairman of the board, comments: “I am honored to have been elected chairman of the board of Orexo, a company with an impressive history, a clear commercial base, and a strong scientific foundation where the technology platform AmorphOX® is at the center. I look forward to working with members of the board and management team, as we step into what I believe is an exciting future for Orexo. Together, I am certain we can create sustainable value – not only for our shareholders but also for patients, caregivers, and partners.”

"I welcome Friedrich von Bohlen as the new chairman of the board and at the same time extend a warm thank you to James Noble for his significant contributions as chairman. James has steadily led Orexo through a period marked by pandemic and geopolitical uncertainty. The company's robust financial position today and EBITDA profitability are largely due to James's efforts, as well as the strategic development of the AmorphOX® technology platform," says Henrik Kjear Hansen, chairman of the nomination committee representing Novo Holdings A/S.

An interview with Friedrich von Bohlen will soon be published on Orexo’s website.

For further information contact:
Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
Tel: +46 18 780 88 00
E-mail: ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs on OTCQX market (ORXOY) in the US.

For more information on Orexo, visit www.orexo.com. Follow Orexo on X, LinkedIn, and YouTube.

The information was submitted for publication at 8.00 am CEST on May 9, 2025.